Can 18F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?;Kann bei Patienten mit malignem Melanom der Haut mit der 18F-FDG PET/CT ein Rezidiv vorher-gesagt werden?

NuklearMedizin

Volumn 50, Issue 3, 2011, Pages 116-121

  Kang, S ^a   Ahn, B C ^a   Hong, C M ^a   Song, B I ^a   Lee, H J ^a   Jeong, S Y ^a   Lee, S W ^a   Lee, J ^a   Lee, S J ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

18F FDG PET CT; Cutaneous malignant melanoma; Predicting recurrence; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PROGNOSIS; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SKIN ULCER;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79957635123     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0356-10-09     Document Type: Article

References (36)

1. Aloj L, Caracó C, Jagoda E et al. Glut-1 and hexo - kinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake inA431 and T47D cells in culture. Cancer Res 1999; 59: 4709-4714.
2. Altekruse SF, Kosary CL, Krapcho M et al. SEER Cancer Statistics Review, 1975-2007. SEER web site, 2010: http://seer.cancer.gov/csr/1975_2007/,
3. Bastiaannet E, Oyen WJ, Meijer S et al. Impact of [18F] fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006; 93: 243-249.
4. Bastiaannet E, Wobbes T, Hoekstra OS et al. Prospective comparison of (18F)fluorodeoxyglucose positron emission tomography and computed tomo graphy in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009; 27: 4774-4780.
5. Bastiaannet E, Hoekstra OS, Oyen WJ et al. Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases. Ann Surg Oncol 2006; 13: 919-926.
6. Bedin V, Adam RL, de Sá BC et al. Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma. BMC Cancer 2010; 10: 260.
7. Boellaard R, Krak NC, Hoekstra OS et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004; 45: 1519-1527.
8. Boni R, Boni RA, Steinert H et al. Staging of metastatic melanoma by whole body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy- D-glucose. Br J Dermatol 1995; 132: 556-562.
9. Chung HW, Lee EJ, Cho YH et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol 2010; 136: 1929-1935.
10. Damian DL, Fulham MJ, Thompson E et al. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 325-329.
11. Eary JF, O'Sullivan F, Powitan Y et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002; 29: 1149-1154.
12. Haberkorn U, Strauss LG, Reisser C et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32: 1548-1555.
13. Homsi J, Kashani-Sabet M, Messina JL et al. Cutaneous melanoma: prognostic factors. Cancer Control 2005; 12: 223-229.
14. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000; 27: 643-646.
15. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
16. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003; 44: 224-239.
17. Krak NC, Boellaard R, Hoekstra OS et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005; 32: 294-301.
18. Kumar R, Mavi A, Bural G et al. Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am 2005; 43: 23-33.
19. Mijnhout GS, Hoekstra OS, van Tulder MW et al. Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomo -graphy in melanoma patients. Cancer 2001; 91: 1530-1542.
20. Minn H, Joensuu H, Ahonen A et al. Fluorodeoxy-glucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776-1781.
21. Minn H, Lapela M, Klemi PJ et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38: 1907-1911.
22. Mochiki E, Kuwano H, Katoh H et al. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004; 28: 247-253.
23. Nakajo M, Kajiya Y, Kaneko T et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 2010; 37: 2011-2020.
24. Oshida M,Uno K,Suzuki M et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2- fluoro(18F)-D-glucose. Cancer 1998; 82: 2227-2234.
25. Oyama N, Akino H, Suzuki Y et al. Prognostic value of 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4: 99-104.
26. Rinne D, Baum RP, Hor G et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer 1998; 82: 1664-1671.
27. Schwimmer J, Essner R, Patel A et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000; 44: 153-167.
28. Song BI, Lee HJ, Kang SM et al. Prognostic significance of maximum SUV of primary tumor and axillary lymph nodes on initial F-18 FDG PET/CT in invasive ductal breast cancer. J Nucl Med 2010; 51 (Suppl): 237P.
29. Spatz A, Batist G, Eggermont AM. The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol 2010; 22: 163-168.
30. Sperti C, Pasquali C, Chierichetti F et al. 18-Fluoro - deoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003; 7: 953-959.
31. Sugawara Y, Quint LE, Iannettoni MD, et al. Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A work in progress. Clin Positron Imaging 1999; 2: 111-118.
32. Van Westreenen HL, Plukker JT, Cobben DC et al. Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol 2005; 185: 436-440.
33. Vansteenkiste J, Fischer BM, Dooms C et al. Positron- emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5: 531-540.
34. Wagner JD, Schauwecker D, Hutchins G et al. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997; 64: 181-189.
35. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of (18F)fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20: 4199-4208.
36. Zimny M, Fass J, Bares R et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000; 35: 883-888.